Phenoxypropazine
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H14N2O |
| Molar mass | 166.224 g·mol−1 |
Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.
See also
| |||||||||||||||||||||
| |||||||||||||||||||||
|
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| Non-specific |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phenethylamines (dopamine, epinephrine, norepinephrine) |
|
||||||||||
|
Tryptamines (serotonin, melatonin) |
|
||||||||||
| Histamine |
|
||||||||||
|